FAP and neoplasm: In order to confirm the binding specificity to FAP, [68Ga]Ga-DOTA-FD1 and excess unlabeled FD1 (750 μg) were co-injected into HT1080-FAP tumor models, in which the cold FD1 competitively bound to and saturated the target.